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ABSTRACT: Optimization of the side-chain of a phenyl
indole scaffold identified from a high-throughput screening
campaign for inhibitors of the AAA+ ATPase p97 is reported.
The addition of an N-alkyl piperazine led to high potency of
this series in a biochemical assay, activity in cell-based assays,
and excellent pharmaceutical properties. Molecular modeling
based on a subsequently obtained cryo-EM structure of p97 in
complex with a phenyl indole was used to rationalize the
potency of these allosteric inhibitors.
KEYWORDS: AAA+ ATPase, p97, allosteric inhibitor, protein homeostasis modulator, anticancer, phenyl indole
The AAA+ (ATPase associated with various cellularactivities) p97 is a hexameric, multidomain protein that
plays a key role in protein homeostasis. Energy from the
hydrolysis of ATP is mechanically relayed by p97 for the
extraction of polypeptides from membranes, the ribosome or
DNA, facilitating polypeptide degradation by the proteasome. In
addition, p97 is hypothesized to play a role in other protein
degradation pathways, including autophagy.1,2 Its essential role
in protein homeostasis and the clinical success of proteasome
inhibitors suggest the potential for targeting certain cancers with
p97 inhibitors. Toward this end, a number of small molecule
inhibitors of p97 have been reported to show promising
antiproliferative effects.3−10 One ATP-competitive active site
inhibitor, CB-5083, advanced to Phase I clinical trials for
multiple myeloma and advanced solid tumors but was recently
discontinued due to off-target retinal toxicity related to
inhibition of PDE6.10−12
As part of our efforts to identify small molecule allosteric
inhibitors of p97,9,13,14 we embarked on a medicinal chemistry
program to optimize a 2-phenyl indole scaffold discovered via a
high-throughput screening (HTS) effort.15 At the time our work
was conducted, no structural information on the compound’s
binding site was available, although it was determined to bind to
an allosteric site.15 A structure−activity relationship (SAR)
study illustrated the importance of the indole moiety for
potency.13,14 In this Letter, we disclose additional SAR data and
the optimization of the flexible side-chain, as well as biological
characterization of key analogs.
Compound 1 (Figure 1 and Table 1) is representative of early
active compounds in the phenyl indole series. Compound 1
inhibited the ATPase activity of p97 with an IC50 = 2.4 μM at
low ATP concentration (20 μM). At higher ATP concentrations
(100 μM), the IC50 improved to 0.99 μM, indicating an
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Figure 1. First-generation phenyl indole inhibitor 1 and areas of
focused SAR explorations.
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uncompetitive binding mechanism.15 Properties (MW, CLogP,
tPSA; ChemDraw) of 1 were all in the drug-like range.
For further optimization, we used an approach that kept the 2-
(3-(piperidin-1-yl)phenyl)-1H-indole scaffold constant and
varied the amine side-chain (Scheme 1). Our synthetic strategy,
which focused on late-stage diversification, relied on previously
optimized Buchwald−Hartwig couplings of 3-bromo-2-phenyl
indoles (2).13,14,16−18 The intermediate, 3, was used for rapid
further diversification via reductive aminations19 to afford, in
some cases after additional modifications, final products of
general structure 4. An alternative strategy relied on direct
coupling of an intact side-chain (or a related analog) with 2 to
generate 4.
Table 1. p97 Inhibitory Activity of Phenyl Indolea
aAssay conditions: ADP-Glo with 20 nM WT p97 in the presence of 100 μM ATP. n denotes number of independent replicates, each assayed in
duplicate or triplicate. In the same assay, the allosteric p97 inhibitor, NMS-873,8 exhibited an IC50 = 11 nM ± 4.9 (n = 13).
Scheme 1. General Synthesis of Phenyl Indoles Using Late-
Stage Diversification Strategies
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The first rounds of SAR were generated from the
unsubstituted 2-phenyl indole core and explored a wide array
of side-chain amines that varied the terminal group as well as the
linker to the piperidine. Replacement of the terminal triazole in 1
with a phenyl group, resulting in analog 5, led to a loss of
potency, indicating the requirement for a polar group at this
position. Replacement with a pyridine (6) restored activity to
near original levels.
The length of the linker appeared to be insignificant, as the 1-
carbon linker (7) possessed equivalent potency to the 2-carbon
analog in this series. Replacement of the aromatic heterocycle
with a piperazine group provided a first significant (∼3-fold)
improvement in potency (8; IC50 = 330 nM) compared to
compound 1.20 Further functionalization by capping the
terminal nitrogen with an aliphatic substituent (e.g., Me, Et,
iPr, tBu; 9−12), provided another boost in potency. In these
examples, the general trend was that greater lipophilicity seemed
to correlate with improved potency, with iPr exhibiting 160 nM
potency. In contrast to compounds 6 and 7, the length of the
linker between the piperidine and the terminal moiety modestly
affected potency: a 3-carbon linker (13) was ∼2-fold less potent
than its 2-carbon homologue 11.
Combining the preferred 5-F indole14,16 with the N-iPr
piperazine afforded 14, the first analog with potency below 100
nM (IC50 = 70 nM). Previous SAR data
13 indicated that the
indole moiety was highly sensitive to modification, and a cryo-
EM co-structure16 and extensive molecular modeling14 showed
the indole deeply embedded in an allosteric binding site in p97’s
D2 domain, located very near the D1−D2 interface, with the
fluorine atom engaging in key interactions with surrounding
residues.14,16 Given the importance of the 5-fluoroindole to
binding and potency, our next iterations maintained this feature
and explored additional amine groups that contained a N-iPr
moiety (see SI).
The terminal amine in the piperazine moiety contributed to
potency, as the truncated dimethyl amino analog 15, while
maintaining some activity (IC50 = 800 nM), was >10-fold less
potent than 14. Modulation of the piperazine nitrogen’s basicity
by introducing a carbonyl group into a 3-carbon linker as in 16
was tolerated, but decreased potency compared to 14. While 16
(IC50 = 190 nM) was slightly more potent than 13 (IC50 = 380
nM), we attributed this difference to the presence of the
potency-enhancing 5-F indole moiety rather than a preference
for the modified linker. We concluded that the length of the
linker was not critical to potency and that the pKa of the internal
piperazine nitrogen could be manipulated without detriment to
biological activity. Taking this information into account, we
attempted to simultaneously constrain the conformation of the
flexible side-chain and reduce the number of basic nitrogen
atoms. This led to the design of analogs such as 17, containing an
amine-linked bis-piperidine side-chain. This compound ex-
hibited strong inhibition of p97 (IC50 = 50 nM) and was
somewhat more potent than compounds containing a flexible
linker, such as 14. While we had no data to suggest specific
liabilities, the elimination of a basic nitrogen was anticipated to
address potential liabilities such as hERG receptor binding and
efflux. To further explore this truncated scaffold, we replaced the
internal piperidine with cis- and trans-cyclohexane groups (see
SI). The trans-analog 18 retained activity toward p97, albeit
∼3−4-fold less than the piperidine 17. In contrast, the cis-isomer
19 was >20-fold less potent compared to the trans-isomer and
>100-fold less potent than 17, indicating a significant conforma-
tional preference. Further shortening and constraining the side-
chain by eliminating the nitrogen linkage (e.g., spiro analog 20;
piperidine-piperazine 21; and fused bicyclo[3.3.0] ring system
22) was not productive. These compounds inhibited p97 in the
micromolar range.
As an alternate approach to conformational constraint, we
incorporated small cyclic moieties as “kinks” into the flexible
linker. This strategy led to some of the most potent analogs in
this series. Cyclobutane 23 inhibited p97 with an IC50 = 20 nM,
i.e., over ten times more potent than the parent analog 9. Based
on SAR trends, this difference could not be attributed solely to
the presence of the 5-F indole in 23. Unlike the flexible linker
series (e.g., 9−11), within this subseries, the N-Me piperazine
terminus (23) was 5-fold more potent than the N-iPr analog
(24). The oxetane analog 25 (IC50 = 90 nM) was similar in
potency to the cyclobutane 24.
To develop structure-based hypotheses to rationalize the
biochemical activity of this series, we utilized a recently reported
cryo-EM costructure of 14 bound to p97; however, while strong
electron-density for the phenyl-indole component of the
inhibitor was observed in this structure, there was no density
detected for the conformationally flexible side-chain.16 As
shown in Figure 2a, the side-chain in the cryo-EM model was
positioned extending out of the allosteric binding cleft and
directly into solvent, making no contacts with the protein.16 This
binding mode was inconsistent with the side-chain SAR, which
indicated a preference for specific, basic groups at this position
Figure 2. (a) Representation of cryo-EM structure of 14 (carbon =
magenta; nitrogen = blue; fluorine = light blue; key hydrogens = white;
yellow dashes = H-bonds) bound to p97 at an allosteric site in the D2
domain.16 The phenyl indole binds in a deep pocket, but the side-chain
points directly into solvent and engages in no contacts with protein
residues. (b) Molecular modeling-derived binding mode that accounts
for side-chain SAR. Key inhibitor (14) side-chain−protein interactions
include H-bonds (yellow dashes) with Gln494, Glu498, Glu534, and
Cys535, as well as solvent shielding of the terminal iPr group by the
side-chain indole of Trp476.
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(e.g., piperazine preferred over pyridine and phenyl, as in 8 vs 6,
5), as well as a preference for lipophilic groups at the piperazine
terminus (e.g., ethyl, iPr, tBu: 10-12 vs H, Me: 8, 9). We
therefore developed a binding model that is consistent with the
available SAR (Figure 2b). Placing the piperidine ring in a chair
conformation (vs the twist chair conformation in the cryo-EM
costructure) allows the basic side-chain of 14 to be oriented
toward the protein and to engage in multiple hydrogen bonds,
instead of extending out into solvent. Favorable interactions
develop between (1) the terminal piperazine nitrogen atom and
the Glu534 carboxylate, (2) the internal piperazine nitrogen
atom and the side-chain amide carbonyl of Gln494, (3) the
secondary amine and Glu498, and (4) the piperidine ring
nitrogen atom (an aniline) and the thiol of Cys535 (an
interaction also observed in the twist chair conformation). Using
this refined model, we were able to rationalize much of the SAR,
particularly that of the side-chain.
Figure 3 shows the proposed binding modes of trans- and cis-
cyclohexanes 18 and 19. The trans-orientation in 18 results in a
favorable binding mode for the side-chain component; hydro-
gen bonds with acidic residues Glu498 and Glu534 are
maintained, and the cyclohexyl component engages in hydro-
phobic contacts with side-chains of Val493 and Ile531.
Additionally, the iPr group orients away from the solvent
toward the aromatic indole side-chain of residue Trp476. In
contrast, binding of the cis-isomer 19 results in a significantly
more solvent-exposed side-chain orientation that forces the
cyclohexyl and iPr groups toward the solvent, an energetically
unfavorable pose. Moreover, the secondary nitrogen atom
engages in unfavorable hydrophobic−polar clashes with the
side-chains of residues Val493 and Ile531. Finally, the
constrained orientation of the cis-isomer results in the loss of a
hydrogen bond with Glu498. The increased potency of 23
compared to compounds resembling 14 can be rationalized by
the binding pose in Figure 4, and the observation that the kinked
side-chain is embedded more deeply into the p97 helix 16−17
interface than the straight-chain analogs, and more fully
occupies a hydrophobic pocket formed by Val493, Ile531
(Figure 4), and, to a lesser degree, Leu 527. We hypothesize that
desolvation of the cyclobutyl group drives this deeper binding
mode. Interestingly, the more buried binding mode of the side-
chain of 23 results in the loss of the H-bond with Glu498
predicted for 14 and a weakening of the H-bond with Glu534
that is observed for 14 (Figure 2b). Rather, the side-chain of 23
engages in H-bonds with the amide side-chains of Gln490 and
494 and forms a favorable cation−π interaction with the side-
chain of Trp476. As noted above, within this gem-disubstituted
cyclobutane subseries, N-Me piperazine is favored over the N-
iPr analog (23 vs 24), in contrast to other members of the class
(e.g., 9 vs 11), where the larger group is preferred. We
hypothesize that the presence of the smaller N-Me substituent is
more sterically compatible with the formation of the cation−π
interaction than larger terminal moieties.
The biochemical potencies of compounds 17 and 23 compare
favorably to another allosteric inhibitor of p97, NMS-873 (IC50=
11 nM)8 in side-by-side comparisons. However, the physical
properties of the phenyl indoles are superior. Specifically, the
aqueous (pH 7.4) solubility (>300 μM) and half-life in in vitro
metabolic stability assays (t1/2 > 270min) in human (HLM) and
mouse liver microsomes (MLM) (Table 2) of 17 and 23 are
Figure 3.Molecular modeling comparison of the binding modes of 18
(a, carbon = cyan) and 19 (b, carbon = orange); yellow dashes = H-
bond; red dashes and spheres = unfavorable interactions. (a) Side-chain
of 18 retains two H-bonds to Glu498 and Glu534, the cyclohexyl group
engages in hydrophobic interactions with Val493 and Ile531, and the
terminal iPr group is located near, and solvent shielded by, the side-
chain indole moiety of Trp476. (b) In contrast, in the model of the cis-
isomer (19) theH-bond toGlu498 is lost; unfavorable interactions (red
dashes and spheres) between the secondary nitrogen and hydrophobic
side chains Val493 and Ile531 are observed, and the cyclohexyl and iPr
groups are significantly more solvent exposed.
Figure 4. Predicted binding mode of 23 (carbon = pink; yellow dashes
= H-bonds). Like other inhibitors of this chemotype, the side-chain
binds down the helix 16/17 interface and engages in multiple hydrogen
bonds with side-chain residues. However, unlike the more flexible
parent 14, the cyclobutyl moiety of 23 binds more deeply in a
hydrophobic pocket at the helical interface. As a result, (1) newH-bond
patterns are formed with the amide side-chains of Gln490 and 494 and
(2) the cyclobutyl moiety engages in closer, more favorable
hydrophobic contacts with the side-chains of Val493 and Ile531, and
(3) the terminal piperazine nitrogen engages in a cation−π interaction
with the side-chain indole of Trp476 (purple dash with terminal, semi-
transparent sphere).
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significantly better; the corresponding value for NMS-873’s
solubility is 86 μM, and its metabolic half-life is <10 min in both
HLM and MLM. The improvement in properties for the phenyl
indoles has facilitated biophysical studies (e.g., cryo-EM
analyses) with these compounds that were not feasible with
NMS-873. Another key difference between this series of
inhibitors and NMS-873 appears to be the nature of the
allosteric inhibition. While NMS-873 exhibits mostly non-
competitive inhibition,9 the phenyl indoles, as a class, are
uncompetitive inhibitors.15,16
We then evaluated whether compounds inhibited p97-
dependent activities in cells. In an assay that measured
accumulation of a ubiquitinated substrate,21−23 17 and 23
showed modest effects at 1 h (EC50 = 19 and 15 μM,
respectively), but the effect was not observed at 6 h even at 40
μM. In contrast, NMS-873 showed robust effects at both 1 and
6 h (EC50 = 1.42 and 2.06 μM, respectively) (Table 2). We
considered several hypotheses to explain this lack of correlation
between biochemical activity (ATPase) and cellular activity
(ubiquitin-mediated degradation). MDCK permeability meas-
urements were uninterpretable, but poor cellular penetration
was considered unlikely based on the high intracellular
concentrations measured for representative analogs (including
14; data not shown).24 A second possibility was that the
uncompetitive mechanism of the phenyl indole inhibitors was
not as efficacious as ATP-competitive (such as CB-5083) or
noncompetitive (such as NMS-873) mechanisms at blocking
p97’s unfoldase activity.15,25−27 Finally, an intriguing possibility
is that the UbG76 V-GFP cellular assay does not recapitulate all of
the diverse functions of p97 and that this phenyl indole class
selectively inhibits only certain p97-dependent functions, such
as autophagy. We have started to evaluate whether other p97-
dependent cellular activities are affected by these phenyl indoles.
Preliminary data suggests this may be the case; these results will
be reported in due course.15
Consistent with blockade of p97, 17 and 23 inhibited cell
growth in the NCI-60 cell line panel.28 Both demonstrated
broad activity in leukemia (pGI50 =−5.7 to−6.7 for 17 and 23);
NSCL cancer (pGI50 = −5.7 to −6.0 for 17; −5.7 to −5.8 for
23); colon cancer (pGI50 = 5.8 to −6.4 for 17; 5.8 to −6.3 for
23); CNS tumor (pGI50 = −5.7 to −5.8 for 17 and 23);
melanoma (pGI50 = −5.7 to −5.9 for 17; −5.7 to −6.5 for 23);
ovarian cancer (pGI50 = −5.7 to −5.8 for 17 and 23); renal
cancer (pGI50 = −5.7 to −5.8 for 17 and 23); prostate cancer
(pGI50 = −5.7 for 17; −5.7 to −5.8 for 23); and breast cancer
(pGI50 = −5.8 for 17; −5.7 to −5.9 for 23) cell lines (see SI).
In conclusion, by applying systematic medicinal chemistry
strategies, we optimized the side-chain region of a series of 2-
phenylindole p97 inhibitors. SAR studies combined with
structural information and molecular modeling were used to
develop a refined bindingmodel suitable for future analog design
iterations. The most potent compounds in this series, such as 17
and 23, exhibit low nanomolar biochemical inhibition of the
ATPase and excellent properties but showed variable effects in
cellular assays that are commonly used to evaluate certain p97-
dependent activities. However, these compounds exhibited
antiproliferative effects in the NCI-60 panel in the high
nanomolar to low micromolar range. Allosteric inhibitors such
as 17 and 23 have the potential to be developed into novel
cancer therapeutics and to be used as chemical biology tools to
interrogate the function of p97 in cancer and other p97-
dependent diseases. Further studies on this series of p97
inhibitors will be reported in due course.
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